Ergoteles’s Neurogene NGNE Stock Holding History

Ergoteles’s Portfolio NGNE Stock Details NGNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-1,202	Closed	-$12.2K	–	1594
2022 Q4	$12.2K	Sell	1,202 -6,364	-84%	-$65.7K	﹤0.01%	1366
2022 Q3	$97K	Sell	7,566 -732	-9%	-$14.9K	﹤0.01%	1391
2022 Q2	$171K	Buy	+8,298	New	+$202K	0.01%	1384

Other funds holding NGNE

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Ergoteles's NGNE Position: Q1 2023 in Review

Ergoteles sold out of Neurogene (NGNE) in Q1 2023, closing a stake of 1,202 shares — an estimated $12.2K sold.

Ergoteles first reported a position in NGNE in Q2 2022 and held it in 3 quarters. The position peaked at $171K in Q2 2022. 39 funds tracked by Wall St. Rank hold NGNE as of Q1 2023.

Ergoteles reported no remaining Neurogene position as of Q1 2023 after selling out during the quarter.
Ergoteles sold 1,202 Neurogene shares in Q1 2023, an estimated $12.2K.
Ergoteles first reported a position in Neurogene in Q2 2022 and held it in 3 quarters.
Ergoteles's Neurogene position peaked at $171K in Q2 2022.
39 funds tracked by Wall St. Rank held Neurogene as of Q1 2023.

Based on Ergoteles's 13F filing for Q1 2023, filed 10 May 2023.